JP2019500327A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500327A5
JP2019500327A5 JP2018523790A JP2018523790A JP2019500327A5 JP 2019500327 A5 JP2019500327 A5 JP 2019500327A5 JP 2018523790 A JP2018523790 A JP 2018523790A JP 2018523790 A JP2018523790 A JP 2018523790A JP 2019500327 A5 JP2019500327 A5 JP 2019500327A5
Authority
JP
Japan
Prior art keywords
adc
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018523790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063990 external-priority patent/WO2017095805A1/en
Publication of JP2019500327A publication Critical patent/JP2019500327A/ja
Publication of JP2019500327A5 publication Critical patent/JP2019500327A5/ja
Ceased legal-status Critical Current

Links

JP2018523790A 2015-11-30 2016-11-29 抗huLRRC15抗体薬物コンジュゲート及びその使用方法 Ceased JP2019500327A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562261092P 2015-11-30 2015-11-30
US62/261,092 2015-11-30
US201662417480P 2016-11-04 2016-11-04
US62/417,480 2016-11-04
PCT/US2016/063990 WO2017095805A1 (en) 2015-11-30 2016-11-29 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Publications (2)

Publication Number Publication Date
JP2019500327A JP2019500327A (ja) 2019-01-10
JP2019500327A5 true JP2019500327A5 (cg-RX-API-DMAC7.html) 2020-01-16

Family

ID=57614453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018523790A Ceased JP2019500327A (ja) 2015-11-30 2016-11-29 抗huLRRC15抗体薬物コンジュゲート及びその使用方法

Country Status (7)

Country Link
US (3) US10188660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383909B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019500327A (cg-RX-API-DMAC7.html)
AU (1) AU2016365114A1 (cg-RX-API-DMAC7.html)
CA (1) CA3006596A1 (cg-RX-API-DMAC7.html)
ES (1) ES2810755T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017095805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188660B2 (en) * 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
JP7079773B2 (ja) 2016-09-14 2022-06-02 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗pd-1抗体及びその使用
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
HRP20231280T1 (hr) 2018-03-13 2024-02-02 Zymeworks Bc Inc. Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe
WO2019195278A1 (en) 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2020086895A1 (en) * 2018-10-24 2020-04-30 Scivera LLC Computer-implemented method for quantifying chemical hazard assessment
WO2020181040A1 (en) 2019-03-06 2020-09-10 Silverback Therapeutics, Inc. Cyclic amino-pyrazinecarboxamide compounds and uses thereof
US20210139477A1 (en) 2019-07-16 2021-05-13 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
WO2021067673A1 (en) * 2019-10-04 2021-04-08 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021102332A1 (en) 2019-11-22 2021-05-27 Silverback Therapeutics, Inc. Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
JPWO2021157601A1 (cg-RX-API-DMAC7.html) * 2020-02-03 2021-08-12
KR20220161395A (ko) * 2020-04-01 2022-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제
EP4157880A4 (en) * 2020-05-29 2024-07-17 New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery METHODS AND COMPOSITIONS FOR TREATING, PREVENTING THE ONSET AND/OR SLOWING THE PROGRESSION OF OSTEOARTHRITIS
MX2023008628A (es) 2021-01-22 2023-09-22 Bayer Ag Anticuerpos lrrc15 y conjugados de los mismos.
CN113181373B (zh) * 2021-05-10 2024-03-01 深圳安特生物医药科技有限公司 一种抗体药物偶联制剂及其制备方法和应用
EP4359428A2 (en) 2021-06-23 2024-05-01 Cytune Pharma Interleukin-15 based immunocytokines
WO2022268991A1 (en) 2021-06-23 2022-12-29 Cytune Pharma Interleukin 15 variants
JP2025534696A (ja) * 2022-10-12 2025-10-17 ミシク セラピューティクス, インコーポレイテッド Lrrc15結合タンパク質構築物及びそれらの使用
JPWO2024158047A1 (cg-RX-API-DMAC7.html) 2023-01-27 2024-08-02
WO2025090749A1 (en) * 2023-10-25 2025-05-01 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting leucine rich repeat containing 15 (lrrc15)
WO2025160129A1 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299216A (en) 1979-10-17 1981-11-10 The United States Of America As Represented By The Secretary Of The Interior Self-contained closed circuit breathing apparatus having a balanced breathing resistance system
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816457A (en) 1980-12-23 1989-03-28 Baldwin John J Aralkylaminoethanol heterocyclic compounds
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
RU2489423C2 (ru) 2006-02-02 2013-08-10 Синтарга Б.В. Водорастворимые аналоги сс-1065 и их конъюгаты
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
AU2008331516B2 (en) 2007-11-28 2014-01-09 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
CA2762877A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
TWI603741B (zh) 2011-06-10 2017-11-01 梅爾莎納醫療公司 蛋白質-聚合物-藥物共軛體
SG11201402686UA (en) 2011-12-05 2014-06-27 Igenica Inc Antibody-drug conjugates and related compounds, compositions, and methods
US20130189218A1 (en) 2011-12-23 2013-07-25 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
EP3095797B1 (en) 2012-02-24 2020-05-20 AbbVie Stemcentrx LLC Anti dll3 antibodies and methods of use thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
EP2928504B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
US10188660B2 (en) * 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法

Similar Documents

Publication Publication Date Title
JP2019500327A5 (cg-RX-API-DMAC7.html)
JP2012136541A5 (cg-RX-API-DMAC7.html)
JP2013517277A5 (cg-RX-API-DMAC7.html)
JP2019524645A5 (cg-RX-API-DMAC7.html)
JP2015531750A5 (cg-RX-API-DMAC7.html)
JP2021504430A5 (cg-RX-API-DMAC7.html)
JP2014237714A5 (cg-RX-API-DMAC7.html)
FI4084791T3 (fi) Spesifisiä tryptamiinejä käytettäviksi mielialahäiriöiden hoidossa
JP2014516991A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2019172710A5 (cg-RX-API-DMAC7.html)
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
FI3083694T3 (fi) Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita
JP2014129395A5 (cg-RX-API-DMAC7.html)
JP2006527762A5 (cg-RX-API-DMAC7.html)
JP2009017881A5 (cg-RX-API-DMAC7.html)
JP2015527319A5 (cg-RX-API-DMAC7.html)
JP2015528818A5 (cg-RX-API-DMAC7.html)
IL281277B1 (en) Compositions and methods for the treatment of viral infections
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2019504086A5 (cg-RX-API-DMAC7.html)
JP2010521147A5 (cg-RX-API-DMAC7.html)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
JP2019031567A5 (cg-RX-API-DMAC7.html)